SMYD1

Summary

SMYD1 (SET and MYND domain containing 1, HGNC:20986) is a protein-coding gene on chromosome 2p11.2, encoding Histone-lysine N-methyltransferase SMYD1 (Q8NB12). Methylates histone H3 at ‘Lys-4’ (H3K4me), seems able to perform both mono-, di-, and trimethylation.

Predicted to enable several functions, including histone H3K4 trimethyltransferase activity; transcription corepressor activity; and zinc ion binding activity. Involved in positive regulation of myoblast differentiation and positive regulation of myotube differentiation. Predicted to be located in cytoplasm. Predicted to be active in nucleus.

Source: NCBI Gene 150572 — RefSeq curated summary.

At a glance

• Gene–disease (curated): hypertrophic cardiomyopathy (Limited, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 110 total
• Druggable target: yes
• MANE Select transcript: NM_198274

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20986
Approved symbol	SMYD1
Name	SET and MYND domain containing 1
Location	2p11.2
Locus type	gene with protein product
Status	Approved
Aliases	BOP, ZMYND22, KMT3D
Ensembl gene	ENSG00000115593
Ensembl biotype	protein_coding
OMIM	606846
Entrez	150572

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 15 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000419482, ENST00000438570, ENST00000444564, ENST00000468008, ENST00000891941, ENST00000891942, ENST00000891943, ENST00000965772, ENST00000965773, ENST00000965774, ENST00000965775, ENST00000965776, ENST00000965777, ENST00000965778, ENST00000965779, ENST00000965780

RefSeq mRNA: 2 — MANE Select: NM_198274 NM_001330364, NM_198274

CCDS: CCDS33240, CCDS82480

Canonical transcript exons

ENST00000419482 — 10 exons

Exon	Start	End
ENSE00001011455	88103058	88103150
ENSE00001011458	88106325	88106488
ENSE00001076273	88096595	88096784
ENSE00001076275	88091012	88091142
ENSE00001286663	88093517	88093555
ENSE00001505800	88108371	88108539
ENSE00001639454	88110354	88113384
ENSE00001750433	88067825	88068001
ENSE00003475280	88087862	88088075
ENSE00003535684	88084316	88084492

Expression profiles

Bgee: expression breadth ubiquitous, 145 present calls, max score 99.46.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 2.3780 / max 493.3774, expressed in 142 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
21339	1.3954	124
21340	0.9567	89
202277	0.0259	9

Top tissues by expression

229 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left ventricle myocardium	UBERON:0006566	99.46	gold quality
vastus lateralis	UBERON:0001379	99.11	gold quality
deltoid	UBERON:0001476	98.98	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.74	gold quality
tibialis anterior	UBERON:0001385	98.70	gold quality
quadriceps femoris	UBERON:0001377	98.68	gold quality
biceps brachii	UBERON:0001507	98.63	gold quality
skeletal muscle tissue	UBERON:0001134	98.58	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.57	gold quality
myocardium	UBERON:0002349	98.47	gold quality
heart right ventricle	UBERON:0002080	98.45	gold quality
hindlimb stylopod muscle	UBERON:0004252	98.24	gold quality
cardiac muscle of right atrium	UBERON:0003379	97.97	gold quality
gastrocnemius	UBERON:0001388	97.89	gold quality
apex of heart	UBERON:0002098	97.78	gold quality
cardiac ventricle	UBERON:0002082	96.88	gold quality
heart left ventricle	UBERON:0002084	96.86	gold quality
muscle of leg	UBERON:0001383	95.93	gold quality
body of tongue	UBERON:0011876	95.43	gold quality
muscle tissue	UBERON:0002385	95.22	gold quality
cardiac atrium	UBERON:0002081	94.57	gold quality
right atrium auricular region	UBERON:0006631	94.47	gold quality
pancreatic ductal cell	CL:0002079	91.81	silver quality
heart	UBERON:0000948	90.64	gold quality
tongue	UBERON:0001723	89.03	gold quality
muscle layer of sigmoid colon	UBERON:0035805	81.73	gold quality
superior surface of tongue	UBERON:0007371	81.34	gold quality
pharyngeal mucosa	UBERON:0000355	79.14	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.82	gold quality
kidney epithelium	UBERON:0004819	75.50	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-HCAD-30	no	78.16
E-ANND-3	no	2.76

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GRHL3, HDGF, MEF2A, MEF2C, MYOG, SRF

Literature-anchored findings (GeneRIF, showing 11)

• effects of gene mutations on ventricular development (PMID:12858532)
• HDGF functions as a transcriptional repressor of the SMYD1 gene through interaction with the transcriptional corepressor CtBP. (PMID:19162039)
• SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma. (PMID:25644430)
• SMYD1 serves as an Serum Response Factor-interacting protein, enhances Serum Response Factor DNA binding activity, and is required for endothelial cell migration and tube formation to regulate angiogenesis. (PMID:26799706)
• We present genetic and statistical evidence that the R320Q substitution in SMYD1 underlies an inherited form of the AnWj-negative blood group phenotype. The mechanism by which the mutation leads to this phenotype remains to be determined. (PMID:29956848)
• This novel mutation (c.814T>C/p.F272L) may be the first identified disease-causing mutation of SMYD1 in Hypertrophic cardiomyopathy (HCM) patients worldwide. (PMID:30205637)
• Modulation of chromatin remodeling proteins SMYD1 and SMARCD1 promotes contractile function of human pluripotent stem cell-derived ventricular cardiomyocyte in 3D-engineered cardiac tissues. (PMID:31097748)
• Stability of Smyd1 in endothelial cells is controlled by PML-dependent SUMOylation upon cytokine stimulation. (PMID:33241844)
• The Methyltransferase Smyd1 Mediates LPS-Triggered Up-Regulation of IL-6 in Endothelial Cells. (PMID:34944023)
• Lysine Methyltransferase SMYD1 Regulates Myogenesis via skNAC Methylation. (PMID:37443729)
• Binding Behavior of Human Hepatoma-Derived Growth Factor on SMYD1. (PMID:39091133)

Cross-species orthologs

13 orthologs

Organism	Symbol	Gene ID
danio_rerio	smyd1a	ENSDARG00000009280
danio_rerio	smyd1b	ENSDARG00000091253
mus_musculus	Smyd1	ENSMUSG00000055027
rattus_norvegicus	Smyd1	ENSRNOG00000006776
drosophila_melanogaster	Smyd3	FBGN0011566
drosophila_melanogaster	dao	FBGN0028862
drosophila_melanogaster	SmydA-9	FBGN0030102
drosophila_melanogaster	SmydA-5	FBGN0033061
drosophila_melanogaster	Smyd4-1	FBGN0033427
drosophila_melanogaster	Smyd4-2	FBGN0036282
drosophila_melanogaster	CG18213	FBGN0038470
drosophila_melanogaster	SmydA-8	FBGN0053548
caenorhabditis_elegans	set-18	WBGENE00044070

Paralogs (5): SMYD5 (ENSG00000135632), ZMYND15 (ENSG00000141497), SMYD2 (ENSG00000143499), SMYD3 (ENSG00000185420), SMYD4 (ENSG00000186532)

Protein

Protein identifiers

Histone-lysine N-methyltransferase SMYD1 — Q8NB12 (reviewed: Q8NB12)

Alternative names: SET and MYND domain-containing protein 1

All UniProt accessions (3): C9JUP3, E9PHG3, Q8NB12

UniProt curated annotations — full annotation on UniProt →

Function. Methylates histone H3 at ‘Lys-4’ (H3K4me), seems able to perform both mono-, di-, and trimethylation. Acts as a transcriptional repressor. Essential for cardiomyocyte differentiation and cardiac morphogenesis.

Subunit / interactions. Interacts with HDAC1, HDAC2 and HDAC3. Interacts (via MYND-type zinc finger) with NACA isoform skNAC.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Expression seems mostly restricted to heart and skeletal muscle.

Domain organisation. The SET domain is split between the S-sequence (residues 1-49) and the core SET domain (residues 181-258), however the two segments still come together to form a conserved SET domain fold.

Induction. By serum response factor SRF and myogenin. SRF binds to the CArG site and MYOG binds to the E-box element on SMYD1 promoter.

Similarity. Belongs to the class V-like SAM-binding methyltransferase superfamily.

RefSeq proteins (2): NP_001317293, NP_938015* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001214	SET_dom	Domain
IPR002893	Znf_MYND	Domain
IPR011990	TPR-like_helical_dom_sf	Homologous_superfamily
IPR044418	SMYD1_SET	Domain
IPR046341	SET_dom_sf	Homologous_superfamily
IPR050869	H3K4_H4K5_MeTrfase	Family

Pfam: PF00856, PF01753

Catalyzed reactions (Rhea), 1 shown:

• L-lysyl(4)-[histone H3] + 3 S-adenosyl-L-methionine = N(6),N(6),N(6)-trimethyl-L-lysyl(4)-[histone H3] + 3 S-adenosyl-L-homocysteine + 3 H(+) (RHEA:60260)

UniProt features (20 total): binding site 16, chain 1, domain 1, sequence variant 1, zinc finger region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NB12-F1	93.07	0.87

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (16): 86; 90; 135; 205–206; 208; 270–272; 274; 276; 279; 17–19; 52; 55 …

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-9733709	Cardiogenesis
R-HSA-1266738	Developmental Biology

MSigDB gene sets: 123 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, GOBP_POSITIVE_REGULATION_OF_MYOTUBE_DIFFERENTIATION, GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_MUSCLE_CELL_DIFFERENTIATION, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_STRIATED_MUSCLE_CELL_DIFFERENTIATION, CAGCTG_AP4_Q5, GOBP_REGULATION_OF_MYOBLAST_DIFFERENTIATION, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_MUSCLE_CELL_DIFFERENTIATION, GOBP_SKELETAL_MUSCLE_ORGAN_DEVELOPMENT, GOBP_MYOBLAST_DIFFERENTIATION, NKX25_01, GOBP_REGULATION_OF_MYOTUBE_DIFFERENTIATION

GO Biological Process (7): heart development (GO:0007507), positive regulation of myotube differentiation (GO:0010831), methylation (GO:0032259), skeletal muscle cell differentiation (GO:0035914), positive regulation of myoblast differentiation (GO:0045663), chromatin remodeling (GO:0006338), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (9): DNA binding (GO:0003677), transcription corepressor activity (GO:0003714), zinc ion binding (GO:0008270), histone H3K4 trimethyltransferase activity (GO:0140999), protein binding (GO:0005515), methyltransferase activity (GO:0008168), transferase activity (GO:0016740), histone H3K4 methyltransferase activity (GO:0042800), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
animal organ development	1
circulatory system development	1
regulation of myotube differentiation	1
myotube differentiation	1
positive regulation of striated muscle cell differentiation	1
metabolic process	1
skeletal muscle tissue development	1
cell differentiation	1
myoblast differentiation	1
positive regulation of cell differentiation	1
regulation of myoblast differentiation	1
chromatin organization	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
nucleic acid binding	1
transcription coregulator activity	1
negative regulation of DNA-templated transcription	1
transition metal ion binding	1
histone H3K4 methyltransferase activity	1
binding	1
transferase activity, transferring one-carbon groups	1
catalytic activity	1
protein-lysine N-methyltransferase activity	1
histone H3 methyltransferase activity	1
cation binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1973 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SMYD1	IRX5	P78411	790
SMYD1	IRX1	P78414	786
SMYD1	HAND2	P61296	785
SMYD1	SMYD5	Q6GMV2	769
SMYD1	A0A3B3ITS8	A0A3B3ITS8	769
SMYD1	E9PD41	E9PD41	762
SMYD1	KCND2	Q9NZV8	737
SMYD1	TTN	Q8WZ42	588
SMYD1	DEAF1	O75398	558
SMYD1	IRX3	P78415	551
SMYD1	IRX6	P78412	533
SMYD1	SETD7	Q8WTS6	513
SMYD1	UBOX5	O94941	505
SMYD1	IRX2	Q9BZI1	501
SMYD1	UNC45B	Q8IWX7	500

IntAct

132 interactions, top by confidence:

A	B	Type	Score
BHLHE40	SMYD1	psi-mi:“MI:0915”(physical association)	0.830
SMYD1	ADSS2	psi-mi:“MI:0914”(association)	0.780
ADSS2	SMYD1	psi-mi:“MI:0915”(physical association)	0.780
SMYD1	ZBTB44	psi-mi:“MI:0915”(physical association)	0.740
ZBTB44	SMYD1	psi-mi:“MI:0915”(physical association)	0.740
SMYD1	UTP14A	psi-mi:“MI:0915”(physical association)	0.670
SMYD1	FAM204A	psi-mi:“MI:0915”(physical association)	0.670
FAM204A	SMYD1	psi-mi:“MI:0915”(physical association)	0.670
UTP14A	SMYD1	psi-mi:“MI:0915”(physical association)	0.670
HOMEZ	SMYD1	psi-mi:“MI:0915”(physical association)	0.560
SMYD1	HOMEZ	psi-mi:“MI:0915”(physical association)	0.560
SMYD1	DISC1	psi-mi:“MI:0915”(physical association)	0.560
SMYD1	KRT35	psi-mi:“MI:0915”(physical association)	0.560
SMYD1	BACH2	psi-mi:“MI:0915”(physical association)	0.560
SMYD1	ZBTB3	psi-mi:“MI:0915”(physical association)	0.560
USP54	SMYD1	psi-mi:“MI:0915”(physical association)	0.560
NEFL	SMYD1	psi-mi:“MI:0915”(physical association)	0.560
POU6F2	SMYD1	psi-mi:“MI:0915”(physical association)	0.560
	SMYD1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (67): SMYD1 (Two-hybrid), SMYD1 (Two-hybrid), SMYD1 (Two-hybrid), SCRN3 (Affinity Capture-MS), ADSS (Affinity Capture-MS), SPSB3 (Affinity Capture-MS), BHLHE40 (Two-hybrid), HOMEZ (Two-hybrid), SMYD1 (Two-hybrid), SMYD1 (Two-hybrid), SMYD1 (Two-hybrid), SMYD1 (Two-hybrid), SMYD1 (Two-hybrid), SMYD1 (Two-hybrid), SMYD1 (Two-hybrid)

ESM2 similar proteins: A0A1L7TZE5, A0A559KX76, A1C7E4, A1CS00, A1DHW6, A2QCU8, A6SDQ3, A7F045, B0XTS1, B2WKR4, B6Q4Z5, B8M7Q5, B8NGT5, O22781, O43463, O54864, P0CY36, P93025, P97443, Q00659, Q0CY32, Q0E908, Q0VD24, Q28CQ7, Q2NL30, Q2UES9, Q2UFN8, Q32PH7, Q4IJ84, Q4R3E0, Q4WVM1, Q4X0A9, Q5BHD6, Q5E9N5, Q5F3W5, Q5I0M0, Q5PP37, Q5RB81, Q60649, Q6DGD3

Diamond homologs: A9CPT4, C3RZA1, D3ZKV9, E1C5V0, F1QN74, F1RET2, O74467, P97443, Q0P585, Q12529, Q3TYX3, Q4VC12, Q5BJI7, Q5F3V0, Q5R5X9, Q5RGL7, Q5UNT8, Q5ZIZ2, Q6C9E7, Q6GMV2, Q6GN68, Q6GPQ4, Q7M6Z3, Q7TSV3, Q7ZXV5, Q8BTK5, Q8IYR2, Q8NB12, Q8R5A0, Q91YE3, Q96E35, Q9BXT4, Q9CQG3, Q9CWR2, Q9D5Z5, Q9GZT9, Q9H7B4, Q9N3Q8, Q9NRG4, A3M0J3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

110 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	99
Likely benign	4
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1583 predictions. Top by Δscore:

Variant	Effect	Δscore
2:88067999:CAGG:C	donor_loss	1.0000
2:88068000:AGGT:A	donor_loss	1.0000
2:88084311:TCCA:T	acceptor_loss	1.0000
2:88084312:CCA:C	acceptor_loss	1.0000
2:88084314:A:AG	acceptor_gain	1.0000
2:88084315:G:GA	acceptor_gain	1.0000
2:88084315:GC:G	acceptor_gain	1.0000
2:88084315:GCC:G	acceptor_gain	1.0000
2:88084315:GCCT:G	acceptor_gain	1.0000
2:88084315:GCCTT:G	acceptor_gain	1.0000
2:88084490:CAGG:C	donor_loss	1.0000
2:88084491:AGG:A	donor_loss	1.0000
2:88084493:G:GA	donor_loss	1.0000
2:88084494:T:A	donor_loss	1.0000
2:88087859:CAGG:C	acceptor_loss	1.0000
2:88087860:A:AG	acceptor_gain	1.0000
2:88087860:AGGCT:A	acceptor_gain	1.0000
2:88087861:G:GG	acceptor_gain	1.0000
2:88087861:GGCT:G	acceptor_gain	1.0000
2:88087861:GGCTG:G	acceptor_gain	1.0000
2:88088051:G:GG	donor_gain	1.0000
2:88088071:GAGTG:G	donor_gain	1.0000
2:88088073:GTG:G	donor_gain	1.0000
2:88088076:G:GG	donor_gain	1.0000
2:88088076:GTAG:G	donor_loss	1.0000
2:88088077:T:G	donor_loss	1.0000
2:88091139:GCAA:G	donor_gain	1.0000
2:88091143:G:GG	donor_gain	1.0000
2:88103056:A:AG	acceptor_gain	1.0000
2:88103057:G:GT	acceptor_gain	1.0000

AlphaMissense

3298 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:88084332:T:C	C52R	1.000
2:88084371:T:C	C65R	1.000
2:88084446:T:C	C90R	1.000
2:88108423:G:T	G400W	1.000
2:88108424:G:A	G400E	1.000
2:88108459:G:T	G412W	1.000
2:88067992:T:A	V43D	0.999
2:88084333:G:A	C52Y	0.999
2:88084334:C:G	C52W	0.999
2:88084343:C:G	C55W	0.999
2:88084371:T:A	C65S	0.999
2:88084372:G:A	C65Y	0.999
2:88084372:G:C	C65S	0.999
2:88084373:T:G	C65W	0.999
2:88084380:T:A	C68S	0.999
2:88084380:T:C	C68R	0.999
2:88084381:G:C	C68S	0.999
2:88084399:G:A	C74Y	0.999
2:88084410:T:C	C78R	0.999
2:88084411:G:A	C78Y	0.999
2:88084412:C:G	C78W	0.999
2:88084446:T:A	C90S	0.999
2:88084447:G:C	C90S	0.999
2:88084448:T:G	C90W	0.999
2:88087864:T:C	L106P	0.999
2:88091063:G:C	G194R	0.999
2:88091064:G:A	G194D	0.999
2:88091064:G:T	G194V	0.999
2:88091070:G:A	G196D	0.999
2:88091105:T:C	C208R	0.999

dbSNP variants (sampled 300 via entrez): RS1000028130 (2:88092766 G>A), RS1000130382 (2:88078666 C>G), RS1000153539 (2:88094918 C>G), RS1000162538 (2:88098579 A>G), RS1000194232 (2:88080576 G>A), RS1000214551 (2:88098935 A>G), RS1000441322 (2:88093038 G>C), RS1000449397 (2:88069020 C>A,G), RS1000476231 (2:88078964 G>A), RS1000542414 (2:88089838 C>T), RS1000572770 (2:88083737 T>C), RS1000637077 (2:88075857 T>C), RS1000678241 (2:88089501 T>C), RS1000728808 (2:88104397 G>A,C,T), RS1000757199 (2:88096401 C>T)

Disease associations

OMIM: gene MIM:606846 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
hypertrophic cardiomyopathy	Limited	Autosomal dominant

Mondo (1): hypertrophic cardiomyopathy (MONDO:0005045)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003542_178	Night sleep phenotypes	3.000000e-08
GCST009959_14	Retinal detachment or retinal break	3.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010698	retinal break

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D002312	Cardiomyopathy, Hypertrophic	C14.280.238.100; C14.280.484.048.750.070.160

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5465333 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

10 total (human), top 10 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression	1
CGP 52608	affects binding, increases reaction	1
incobotulinumtoxinA	decreases expression	1
Sunitinib	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Doxorubicin	decreases expression	1
Estradiol	affects binding, increases reaction	1
Folic Acid	increases expression	1
Triclosan	decreases expression	1
Valproic Acid	increases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5318657	Binding	Inhibition of SMYD1 (unknown origin) at 50 uM	Structure-Activity Relationship Studies of Venglustat on NTMT1 Inhibition. — J Med Chem

Clinical trials (associated diseases)

227 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00879060	PHASE4	COMPLETED	Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
NCT01721967	PHASE4	COMPLETED	Ranolazine for the Treatment of Chest Pain in HCM Patients
NCT02948998	PHASE4	UNKNOWN	Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
NCT03249272	PHASE4	TERMINATED	Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
NCT04133532	PHASE4	COMPLETED	Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy
NCT06401343	PHASE4	RECRUITING	Use of SGLT2i in noHCM With HFpEF
NCT07103655	PHASE4	NOT_YET_RECRUITING	The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
NCT07600177	PHASE4	RECRUITING	Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT00317967	PHASE3	COMPLETED	Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart
NCT00698074	PHASE3	UNKNOWN	Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy
NCT00821353	PHASE3	COMPLETED	Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
NCT02431221	PHASE3	WITHDRAWN	Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure
NCT03470545	PHASE3	COMPLETED	Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT05174416	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
NCT05182658	PHASE3	ACTIVE_NOT_RECRUITING	Empagliflozin in Hypertrophic Cardiomyopathy
NCT05186818	PHASE3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
NCT05767346	PHASE3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT06116968	PHASE3	COMPLETED	An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
NCT06873828	PHASE3	NOT_YET_RECRUITING	Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
NCT07021976	PHASE3	RECRUITING	A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT07023341	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07202897	PHASE3	NOT_YET_RECRUITING	LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
NCT00001631	PHASE2	COMPLETED	Study of Blood Flow in Heart Muscle
NCT00001894	PHASE2	COMPLETED	A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy
NCT00001960	PHASE2	COMPLETED	Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle
NCT00011076	PHASE2	COMPLETED	Pirfenidone to Treat Hypertrophic Cardiomyopathy
NCT00035386	PHASE2	COMPLETED	Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
NCT00430833	PHASE2	UNKNOWN	CHANCE - Candesartan in Hypertrophic Cardiomyopathy
NCT00500552	PHASE2	COMPLETED	Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy
NCT01150461	PHASE2	COMPLETED	Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
NCT01230918	PHASE2	TERMINATED	Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis
NCT01447654	PHASE2	COMPLETED	Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy
NCT01696370	PHASE2	UNKNOWN	Trimetazidine Therapy in Hypertrophic Cardiomyopathy
NCT01912534	PHASE2	COMPLETED	Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
NCT02590809	PHASE2	COMPLETED	Hypertrophic Cardiomyopathy Symptom Release by BX1514M
NCT03496168	PHASE2	COMPLETED	Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
NCT03532802	PHASE2	COMPLETED	The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.
NCT03832660	PHASE2	COMPLETED	Sacubitril/Valsartan vs Lifestyle in Hypertrophic Cardiomyopathy
NCT04219826	PHASE2	COMPLETED	Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
NCT04426578	PHASE2	UNKNOWN	Role of Perhexiline in Hypertrophic Cardiomyopathy